IDO/TDO Inhibitor Compound Design

The patent applies universality by designing a single compound structure (formula I) that can inhibit both IDO and TDO enzymes. The compound contains a core structure with specific substituents (R1, R2, R3, R4, R5, R6, R7, R8) that can be optimized to interact with both enzyme types, enabling one agent to perform multiple therapeutic functions across different disease states where either enzyme may be relevant.

The patent employs parameter changes by systematically varying the chemical structure parameters of the inhibitor compound (different substituents at various positions on the core structure) to optimize binding affinity for both IDO and TDO enzymes. This allows tuning of the molecular properties to achieve effective inhibition of both enzymes simultaneously, overcoming the limitation of previous inhibitors that were optimized for only one enzyme.

The patent resolves the complexity issue by using a unified core molecular structure that inherently provides the capability to bind both IDO and TDO enzymes. Rather than designing separate complex structures for each enzyme or using a mixture of compounds, a single versatile scaffold (formula I) is employed with modifiable substituents, simplifying the overall therapeutic approach while maintaining broad coverage.

The patent applies segmentation by dividing the molecular structure into a core framework and variable substituent regions (R1-R8). This modular approach allows the core structure to provide the essential binding capability for both enzymes, while the substituents can be optimized independently to fine-tune affinity and selectivity, thereby managing structural complexity in a systematic way.

The patent applies local quality by introducing different substituents at specific positions on the core molecular structure to create regions with distinct binding characteristics. Certain substituents (R1-R8) can be optimized to interact with specific features of IDO or TDO active sites, allowing the compound to maintain high affinity for both enzymes while preserving necessary selectivity through localized structural variations rather than uniform modifications.

The patent uses parameter changes by systematically modifying the chemical properties of substituents (such as hydrophobicity, electronegativity, steric bulk) at different positions on the core structure to optimize the balance between affinity and selectivity. This allows fine-tuning of the compound's interaction with each enzyme's active site to achieve potent inhibition while maintaining appropriate enzyme preference based on therapeutic needs.